Calidi Biotherapeutics, Inc.
CLDI · AMEX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $427 | $0 | $0 | $393 |
| Gross Profit | -$427 | $0 | $0 | -$393 |
| % Margin | – | – | – | – |
| R&D Expenses | $2,361 | $2,593 | $2,425 | $1,815 |
| G&A Expenses | $0 | $3,071 | $2,637 | $0 |
| SG&A Expenses | $2,260 | $3,071 | $2,637 | $1,818 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $4,621 | $5,664 | $5,062 | $3,633 |
| Operating Income | -$5,048 | -$5,664 | -$5,062 | -$4,026 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$123 | -$93 | $3 | -$119 |
| Pre-Tax Income | -$5,171 | -$5,757 | -$5,059 | -$4,145 |
| Tax Expense | $10 | $4 | $3 | $3 |
| Net Income | -$5,149 | -$5,715 | -$4,986 | -$4,097 |
| % Margin | – | – | – | – |
| EPS | -2.21 | -1.99 | -2.21 | -3.22 |
| % Growth | -11.1% | 10% | 31.4% | – |
| EPS Diluted | -2.21 | -1.99 | -2.21 | -3.22 |
| Weighted Avg Shares Out | 4,907 | 2,877 | 2,248 | 664 |
| Weighted Avg Shares Out Dil | 4,907 | 2,877 | 2,248 | 664 |
| Supplemental Information | – | – | – | – |
| Interest Income | – | $0 | $0 | $0 |
| Interest Expense | $41 | $52 | $72 | $175 |
| Depreciation & Amortization | $427 | $407 | $394 | $393 |
| EBITDA | -$4,703 | -$5,298 | -$4,593 | -$3,577 |
| % Margin | – | – | – | – |